4
Changes in Ownership
MapLight Therapeutics, Inc. Filed Acc 0002021238-26-000010
Chief Discovery Officer sold 36,284 shares at an average $37.09 ($1,345,894)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Kreitzer Anatol · Chief Discovery Officer
Table I: Non-derivative
7 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-07-15 | Sale : show line 1 in the form 10b5-1 | −5,545 | $36.13 | $200,341 | 205,645 | D |
| 2026-07-15 | Sale : show line 2 in the form 10b5-1 | −4,510 | $36.94 | $166,599 | 201,135 | D |
| 2026-07-16 | Sale : show line 3 in the form 10b5-1 | −7,464 | $36.66 | $273,630 | 193,671 | D |
| 2026-07-16 | Sale : show line 4 in the form 10b5-1 | −1,592 | $37.44 | $59,604 | 192,079 | D |
| 2026-07-17 | Sale : show line 5 in the form 10b5-1 | −2,833 | $37.05 | $104,963 | 189,246 | D |
| 2026-07-17 | Sale : show line 6 in the form 10b5-1 | −14,140 | $37.70 | $533,078 | 175,106 | D |
| 2026-07-17 | Sale : show line 7 in the form 10b5-1 | −200 | $38.39 | $7,678 | 174,906 | D |
| Open-market sales · 36,284 sh · avg $37.09 · $1,345,894 | ||||||
Loading xslF345X06/form4-07202026_060701.xml…